/

VYGR

Voyager Therapeutics, Inc.Closed

2.15−0.12 −5.29%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 2.19 +1.86%

Open

2.24

Prev close

2.27

Day range

2.142.26

52-week range

2.145.55

Volume

1.06M1.85×

Mkt cap

132.48M

P/E ttm

—

Fwd P/E

-1.68

EPS ttm

-1.81

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−61.26%

Price Chart

Yahoo Finance · delayed

VYGROct 12, 2026O 2.46H 2.47L 2.25C 2.27−0.18 (−7.35%)Vol 967.00K

SMA 503.07
SMA 2003.61

1Y change −54.60% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

VYGR Voyager Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −7.72%
1 month: −28.84%
3 months: −29.94%
6 months: −40.89%
Year to date: −42.24%
1 year: −54.60%

Valuation & ownership

Market cap: 132.48M
Enterprise value: 48.71M
P/E (ttm): —
Forward P/E: -1.68
PEG ratio: —
Price / book: 0.85
Price / sales (ttm): 3.84
EV / EBITDA: -0.44
EPS (ttm): -1.81
EPS (forward): -1.28
Beta (5y monthly): 1.28
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 61.62M
Float: 44.47M
Short % of float: 7.55%
Short ratio (days): 7.57
Held by insiders: 14.84%
Held by institutions: 57.93%
Avg volume (3m): 572.18K
50-day average: 3.07
200-day average: 3.61
52-week change: −54.60%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 23.9
vs 50-day SMA: −26.16%
vs 200-day SMA: −37.05%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.70%
Realised vol (20d, ann.): 56.6%
From 52-week high: −59.10%
From 52-week low: +0.89%

ANR

Analyst Consensus

9 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

14.89

+592.51% implied

Low 8.00Median 12.00High 25.00

Recommendation trend

Now11 / 0 / 0
1m ago11 / 0 / 0
2m ago

DES

About Voyager Therapeutics, Inc.

Yahoo Finance profile

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 141
Headquarters: Lexington, MA, United States
Website: voyagertherapeutics.com
Officers: Dr. Alfred W. Sandrock Jr., M.D., Ph.D. President, CEO & Director
Ms. Robin Swartz Principal Financial Officer, Treasurer, Chief Business Officer & COO
Dr. Krystof Bankiewicz M.D., Ph.D.

SEAS

Seasonality · VYGR

2015–2026 · monthly returns

Strongest month Sep +7.15%Weakest month Nov −7.86%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-0.8	5.1	-5.9	-3.4	3.8	-9.6	-13.4	13.9	-22.3	-19.8			−45.3%
2025	-3.9	-25.1	-17.2	5.3	-23.0	13.5	2.6	5.3	39.0	0.0	-12.4	-3.9	−30.7%
2024	-13.9	14.4	11.9	-16.0	7.4	-5.8	16.2	-28.6	-10.8	16.8	0.4	-17.3	−32.8%
2023	54.8	-23.9	7.4	-6.0	57.1	0.5	-18.6	7.5	-22.7	-15.2	10.5	16.3	+38.4%
2022	5.5	38.8	91.9	-3.8	-17.3	-2.5	13.4	-10.9	-0.8	-12.5	14.7	2.7	+125.1%
2021	5.6	-24.9	-16.9	2.3	-11.6	-3.1	-23.7	3.5	-19.3	37.6	-16.0	-10.9	−62.1%
2020	-20.9	-1.2	-16.1	18.1	11.9	4.3	-12.3	6.5	-9.5	-0.4	-21.7	-14.1	−48.7%
2019	11.6	43.0	27.6	10.2	3.4	24.8	-19.1	-18.8	-3.7	-10.6	-11.4	2.3	+48.4%
2018	24.3	39.2	-34.6	-3.4	9.4	-1.7	-3.5	15.3	-13.0	-28.3	-16.0	-17.5	−43.4%
2017	-6.4	8.6	2.2	-21.1	-15.1	1.1	-8.0	17.0	113.6	2.3	-30.5	13.5	+30.3%
2016	-51.2	-10.4	-8.8	33.4	19.1	-20.8	34.1	-17.4	-1.3	-0.1	3.8	2.2	−41.8%
2015												-13.1	−13.1%

INSD

Insider Activity · VYGR

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Apr 1, 2026	Sandrock AlfredChief Executive Officer	Sale at price 3.87 per share.	11.5K	$44.55K
Mar 31, 2026	Shiferman Gregory LGeneral Counsel	Stock Award(Grant) at price 0.00 per share.	50K	—
Feb 23, 2026	Sandrock AlfredChief Executive Officer	Sale at price 3.79 per share.	14.2K	$53.81K
Feb 23, 2026	Jorgensen Nathan D.Chief Financial Officer	Sale at price 3.77 per share.	4.7K	$17.60K
Feb 23, 2026	Swartz RobinChief Operating Officer	Sale at price 3.77 per share.	6.5K	$24.35K
Feb 23, 2026	Carter Todd AlfredOfficer	Sale at price 3.76 per share.	4.2K	$15.69K
Feb 17, 2026	Sandrock AlfredChief Executive Officer	Sale at price 3.41 per share.	11.7K	$40.01K
Feb 17, 2026	Swartz RobinChief Operating Officer	Sale at price 3.44 per share.	3.9K	$13.35K
Feb 17, 2026	Carter Todd AlfredOfficer	Sale at price 3.44 per share.	3.3K	$11.36K
Feb 9, 2026	Sandrock AlfredChief Executive Officer	Sale at price 3.78 per share.	12.2K	$46.09K
Feb 9, 2026	Swartz RobinChief Operating Officer	Sale at price 3.85 per share.	4.6K	$17.59K
Feb 9, 2026	Carter Todd AlfredOfficer	Sale at price 3.85 per share.	3.5K	$13.57K
Feb 5, 2026	Swartz RobinChairman of the Board	Stock Award(Grant) at price 0.00 per share.	45K	—
Feb 5, 2026	Carter Todd AlfredOfficer	Stock Award(Grant) at price 0.00 per share.	33K	—
Feb 5, 2026	Ferguson TobyOfficer	Stock Award(Grant) at price 0.00 per share.	45K	—
Feb 5, 2026	Sandrock AlfredChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	86.3K	—
Feb 5, 2026	Jorgensen Nathan D.Chief Financial Officer	Stock Award(Grant) at price 0.00 per share.	32.3K	—
Oct 2, 2025	Jorgensen Nathan D.Chief Financial Officer	Sale at price 4.78 per share.	7.7K	$36.64K
Aug 17, 2025	Ferguson TobyOfficer	Sale at price 3.73 per share.	19K	$70.87K
Apr 1, 2025	Sandrock AlfredChief Executive Officer	Sale at price 3.43 per share.	10.9K	$37.34K

13F

Investors Holding VYGR

latest 13F filings of 29 followed managers

Investors holding VYGR
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$1.7M	0.00%	495.24K	−14%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

VYGR

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

VYGR

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Voyager Therapeutics, Inc.

Seasonality · VYGR

Insider Activity · VYGR

Congress Trades · VYGR

Investors Holding VYGR

Investors Holding VYGR

Congress Trades · VYGR

Insider Activity · VYGR

Seasonality · VYGR

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Voyager Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News